TITLE

DRAXIS GETS ACCEPTABILITY AFTER INSPECTION OF MANUFACTURING

PUB. DATE
July 2007
SOURCE
Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the notification given by the U.S. Food and Drug Administration (FDA) to Draxis Health Inc., following the FDA inspection of its manufacturing operations in Montreal, Quebec. The FDA has notified Draxis that its facilities maintain its acceptability. The FDA has inspected the facilities of Draxis Pharma which manufactures sterile lyophilization products.
ACCESSION #
25547357

 

Related Articles

  • CDER Forms Up Pharmaceutical Inspectorate. Haystead, John // Pharmaceutical Technology;Apr2003, Vol. 27 Issue 4, p15 

    Reports that the U.S. Food and Drug Administration's Center for Drug Evaluation and Research has formed a uniquely-focused group of specialists to conduct inspections of pharmaceutical manufacturing facilities. Need of specialized knowledge and skills in the use of increasingly-advanced...

  • Overhauling Compliance and GMPs. Wechsler, Jill // Pharmaceutical Technology;Apr2003, Vol. 27 Issue 4, p22 

    Discusses the U.S. Food and Drug Administration's initiative to develop a risk-based approach to good manufacturing practice regulation of the pharmaceutical industry. Changes in plant inspection policies; Establishment of pharmaceutical inspectorate; Reduction in disputes involving inspection...

  • Govt. keen on having domestic regulators during US-FDA inspections.  // FRPT- Chemical Snapshot;1/25/2015, p2 

    The article reports on the move of the Indian government to request the U.S. Food and Drug Administration (FDA) to allow its domestic regulators during inspections of pharmaceutical companies.

  • Lyophilization Experts Show How to Avoid Common Formulation Mistakes. Rios, Maribel // Pharmaceutical Technology;Dec2005, Vol. 29 Issue 12, p30 

    The article presents experts' views on lyophilization techniques to avoid formulation mistakes. The U.S. Food and Drug Administration is paying close attention to lyophilization data and questioning pharmaceutical companies about their development cycles related to lyophilization process. This...

  • Review of FDA Warning Letters. Moldenhauer, Jeanne // Pharmaceutical Technology Europe;Apr2011, Vol. 23 Issue 4, p44 

    FDA warning Letters offer insight into the concerns of inspectors and can be used to help prepare for an upcoming inspection. The author reviews Warning Letters issued between 2000 and mid-2010 for aseptic processing and non-sterile processing, and determines how many observations were made for...

  • Survival Guide to FDA Inspections. Lavian, Massoud; Allen, Paul W. // BioPharm International;Aug2002, Vol. 15 Issue 8, p20 

    Provides a survival guide to U.S. Food and Drug Administration inspections in the pharmaceutical and biotechnology companies. Types of quality systems that are usually included during an inspection; Quality of the validation programs of the company; Examination of batch records; Examination of...

  • GMP Progress Report. Weschler, Jill // BioPharm International;Apr2003, Vol. 16 Issue 4, p18 

    Reports on regulatory changes to pharmaceutical manufacturing and product quality implemented by the U.S. Food and Drug Administration. Overview of the electronic record-keeping policy; Compliance inspections; Prevention of delays in the approval of new products. INSET: Working Together.

  • We Need More Overseas Inspections. Drakulich, Angie // Pharmaceutical Technology;Oct2007, Vol. 31 Issue 10, p18 

    The author expresses her concern regarding the result of the foreign inspection conducted by the U.S. Food and Drug Administration (FDA) to pharmaceutical manufacturing plants. She cites states that the number of overseas inspections conducted by FDA is inadequate. On the other hand, the budget...

  • Flu-Vaccine Shortage. Klotter, Jule // Townsend Letter for Doctors & Patients;Nov2005, Issue 268, p29 

    Reports on the failure of the U.S. Food and Drug Administration (FDA) to perform regular biennial inspections of all plants that manufacture drugs for the country. Shortage of the supply of influenza vaccine caused by manufacturing problems; Safety issue faced by the agency about the oversight...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics